In summary, mepolizumab, an anti-IL-5 monoclonal antibody used for severe eosinophilic asthma, may inadvertently increase the risk of opportunistic infections, including COVID-19, by altering the immune system dynamics. Here, IL5 is linked to Opportunistic infection.